Compare AREN & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AREN | SCLX |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | 34 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.3M | 52.5M |
| IPO Year | 2017 | N/A |
| Metric | AREN | SCLX |
|---|---|---|
| Price | $0.90 | $9.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 188.9K | 119.0K |
| Earning Date | 05-08-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 191.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,892,000.00 | N/A |
| Revenue This Year | N/A | $122.52 |
| Revenue Next Year | $5.00 | $186.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 27.46 | N/A |
| 52 Week Low | $0.81 | $4.20 |
| 52 Week High | $7.85 | $34.27 |
| Indicator | AREN | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 34.84 | 63.02 |
| Support Level | $0.81 | $7.73 |
| Resistance Level | $1.61 | $12.32 |
| Average True Range (ATR) | 0.11 | 0.94 |
| MACD | 0.02 | 0.24 |
| Stochastic Oscillator | 21.40 | 78.36 |
The Arena Group Holdings Inc is a tech-powered media company that fuses technology, iconic brands, and marketing to deliver vibrant content and experiences that reach million users each month. The company creates robust digital destinations that delight consumers with powerful journalism, news about things such as favorite sports teams, advice on investing, the inside scoop on personal finance, and the latest on lifestyle essentials. The company has four reportable segments: Sports & Leisure, Finance, Lifestyle, and Platform & Other. The company generates revenue from Sports & Leisure. Geographically, the company operates in United States; and Others. It generates maximum revenue from United States.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.